Safety of lidocaine-prilocaine cream in the treatment of preterm neonates.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 8523173.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The safety of lidocaine-prilocaine cream (EMLA) was evaluated in an open trial in 30 preterm neonates (mean gestational age, 32.8 weeks; birth weight, 1911 gm); 0.5 gm was applied to the heel for 1 hour. Mean baseline and follow-up (4, 8, or 12 hours after EMLA application) methemoglobin levels were not different, ranging from 1.15% to 1.45%, and from 1.13% to 1.49%, respectively.
Medical subject headings
- Analgesics
- Consumer Product Safety
- Infant, Premature
- Lidocaine
- Prilocaine